Today: 21 July 2026
AST SpaceMobile stock today: ASTS ticks up after hours on AT&T satellite beta update, insider buy filing
30 December 2025
2 mins read

AST SpaceMobile stock today: ASTS ticks up after hours on AT&T satellite beta update, insider buy filing

NEW YORK, December 29, 2025, 18:16 ET — After-hours

  • AST SpaceMobile shares closed down 0.7% Monday and were last up about 0.7% in after-hours trading.
  • AT&T outlined satellite-to-cell milestones and a 2026 beta plan in a new blog post.
  • A regulatory filing showed an AST director bought shares at $80 last week under a pre-arranged trading plan.

AST SpaceMobile (ASTS) shares closed down 0.7% at $71.47 on Monday and were last up about 0.7% at roughly $72.00 in after-hours trading. The stock ranged from $69.69 to $74.89 during the session.

The move matters because AST SpaceMobile sits at the center of a race to add satellite coverage to everyday smartphones, a theme that has made the stock prone to sharp swings on each new milestone.

Investors are looking for concrete markers that the company can turn launches, testing and carrier partnerships into a scalable service. That keeps the spotlight on timelines, network readiness and funding.

AT&T, a key partner, on Monday pointed to progress on the ground infrastructure that links satellite service into its terrestrial network and flagged a 2026 rollout path. “Beta satellite service in the first half of next year, with commercial launch to follow,” wrote Robert Walters, an AT&T senior vice president, in a company blog post. AT&T Newsroom

The post said AT&T has brought a fourth “ground gateway” online — an earth station that routes traffic between satellites and the carrier’s network — and said agencies in Texas and Colorado have connected over AST’s satellites in orbit.

A separate disclosure also drew attention. A Form 4 filing showed AST director Keith Larson bought 625 shares at $80 on Dec. 24 through an IRA, lifting his indirect holdings to 2,015 shares; the filing said the trade was made under a Rule 10b5-1 plan adopted in September.

AST’s modest decline during regular trading came as broader U.S. equities slipped, with the S&P 500 proxy SPY down 0.4% and the tech-heavy QQQ down 0.5%. Satellite-communications peers Iridium Communications and Viasat also edged lower.

AST SpaceMobile is building a space-based cellular broadband network aimed at connecting directly with standard, unmodified smartphones — often called “direct-to-device” service. The company said last week it launched its first next-generation satellite, BlueBird 6, designed to support 4G and 5G services from space. Business Wire

Traders are now watching for signs that the company can keep a steady launch cadence and convert field tests into a broader beta. AT&T’s comments about additional launches into early 2026 add a near-term scoreboard for that execution story.

Funding remains another watch point for a capital-intensive constellation buildout. In its latest quarterly filing, AST reported $1.204 billion of cash and cash equivalents as of Sept. 30, 2025, and said it had an at-the-market equity program with $517.6 million remaining as of the report date.

Competitive pressure in satellite-to-phone connectivity is rising as carriers and satellite operators chase coverage in remote areas. That raises the stakes for spectrum access, regulatory clearances and dependable satellite performance.

From a trading perspective, Monday’s low near $70 is the first level many investors will be watching into Tuesday’s session. The day’s high just under $75 marks the next nearby resistance on the chart.

Khadija Saeed is a financial markets reporter at TS2.tech, specializing in stocks, technology and emerging industries. She studied economics and finance at the London School of Economics and previously worked in market research before moving into financial journalism. Her coverage focuses on the companies, innovations and economic trends influencing global investors. Follow Khadija Saeed on Google News.

Stock Market Today

  • Vertex Pharmaceuticals (VRTX) Falls as Broader Market Slides Before Earnings Release
    July 20, 2026, 8:02 PM EDT. Vertex Pharmaceuticals (VRTX) ended the session at $478.09, down 1.02%, underperforming the S&P 500's 0.18% decline. VRTX has gained 3.89% in the past month, trailing behind the S&P 500's 4.46% advance. Investors are awaiting Vertex's Q3 earnings, expected on November 4, 2024, with forecasts pointing to EPS of $4.13, an increase of 1.23%, and revenue of $2.68B, up 7.79%. Shares currently trade at a high forward P/E of 7790.32 and a Zacks Rank of #3 (Hold).
Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs
Previous Story

Eli Lilly stock today: LLY inches up as weight-loss pill pricing, insider filing keep spotlight on obesity drugs

Freeport-McMoRan (FCX) stock slides as metals retreat from record highs; Fed minutes next
Next Story

Freeport-McMoRan (FCX) stock slides as metals retreat from record highs; Fed minutes next

Go toTop